Longitudinal Change in Fasting Blood Glucose and Myocardial Infarction Risk in a Population Without Diabetes

Diabetes Care 2017;40:1565–1572 | https://doi.org/10.2337/dc17-0610

OBJECTIVE
To examine the change in fasting blood glucose (FBG) during repeated assessments over time and its potential impact on the risk of developing myocardial infarction (MI).

RESEARCH DESIGN AND METHODS
This prospective cohort study included 68,297 participants without diabetes (mean age 49 years) who were free of MI, stroke, and cancer prior to or in 2010 (baseline of the current analysis). FBG concentrations were measured in 2006, 2008, and 2010. The FBG trajectories during 2006–2010, the primary exposure of the current study, were identified by latent mixture modeling. Incident MI cases were confirmed via review of medical records by cardiologists.

RESULTS
We identified five discrete FBG trajectories according to FBG range and changing pattern over time: elevated-stable (n = 3,877), elevated-decreasing (n = 7,060), moderate-increasing (n = 10,298), moderate-stable (n = 40,352), and low-stable (n = 6,710). During 4 years of follow-up, we documented 283 incident MI cases. Relative to the moderate-stable pattern (FBG ranged from 4.9 to 5.1 mmol/L), adjusted hazard ratios (HRs) were 1.53 (95% CI 1.04, 2.26) for the elevated-stable pattern (FBG ranged from 6.1 to 6.3 mmol/L) and HR 0.61 (95% CI 0.38, 0.98) for the elevated-decreasing pattern (FBG decreased from 6.0 to 5.4 mmol/L), after adjustment for potential confounders such as age, sex, lifestyle factors, obesity, medical history, blood pressure, blood lipids, and C-reactive protein. Consistently, cumulative average and increasing rate of FBG during 2006–2010, but not a single baseline FBG, predicted future risk of MI.

CONCLUSIONS
We found that discrete FBG trajectories were significantly associated with subsequent risk of MI in individuals without diabetes. These observations suggest that long-term trajectories of FBG may be important for risk prediction of MI and possibly other macrovascular diseases.

Diabetes is a major risk factor for atherosclerosis, coronary heart disease (CHD), and premature death (1–3). It has been thought that the risk of developing myocardial infarction (MI) might already be present at glucose concentrations below the current cutoff for diabetes. Some (4–7) but not all studies (8,9) showed that higher fasting blood glucose (FBG) concentrations were associated with higher CHD risk in individuals

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.
without diabetes. It is worth noting that the majority of published studies (2–5) on this topic were based on a single measure of FBG, failing to take into account the potential effect of change in FBG concentrations over time. Not accounting for time-varying and cumulative average of FBG over time could bias the true relation between FBG and MI risk toward the null hypothesis. Further, although MI presents suddenly, the advanced extensive complex intramural lesions that lead to plaque rupture develop over decades. Thus, prospective studies that evaluate the effects of long-term FBG trajectory patterns on MI are essential.

Therefore, the aims of this study were to identify subgroups of individuals with similar trajectories and to compare the MI risk among participants who experienced a stably high level of FBG or a fast increase in FBG with those who maintained an ideal and stable FBG level. We prospectively examined the potential impact of FBG trajectories, based on repeated longitudinal assessments of FBG over 4 years, on the risk of developing MI in over 68,000 adults without diabetes. In secondary analyses, we also examined whether a single measure of FBG at baseline and cumulative average, annual increasing rate, and variability of FBG concentrations in the preceding 4 years were associated with future risk of MI.

RESEARCH DESIGN AND METHODS

Study Design and Population

The Kailuan study is a prospective cohort study designed to investigate the risk factors for common noncommunicable diseases (10–13). In brief, all 155,418 active and retired employees aged 18 years or older of the Kailuan Group, Tangshan, China, were invited to participate in 2006. A total of 101,510 participants (81,110 men and 20,400 women, aged 18–98 years) agreed to participate and completed the first survey from June 2006 to October 2007 (referred to as the 2006 survey here). There were no significant demographic differences between those who agreed to participate in the study and those who declined to join except for a variation in sex distribution (79.9% of participants were men, whereas 85.9% of all Kailuan Group employees were men). All participants underwent questionnaire assessments, physical examinations, and laboratory tests in the 11 hospitals responsible for the health care of the Kailuan community. These participants were followed biennially to update their status on the aforementioned parameters.

In the current study, we identified glucose trajectory patterns using FBG concentrations in 2006, 2008, and 2010 and used the patterns to predict incident MI after 2010 (baseline of the current study, flowchart shown in Supplementary Fig. 1). We excluded 1,239 participants who did not have 2006 FBG data and 14,755 participants without 2008 and 2010 FBG data. Those participants who were excluded from the current analyses due to missing FBG data were older (58.4 vs. 50.7 years, \( P < 0.001 \)) and more likely to be men (88.6 vs. 78.5%, \( P < 0.001 \)) but had similar future MI risk (age- and sex-adjusted hazard ratio (HR) 1.12 [95% CI 0.98, 1.30]), relative to those with completed FBG data. We further excluded 12,993 participants with diabetes (defined as a self-reported physician-diagnosis history, currently treated with insulin or oral hypoglycemic agents, or an FBG concentration \( \geq 7.0 \) mmol/L); 3,621 participants with MI, stroke, or cancer in or prior to 2010; and 605 participants who died during 2006 to 2010. The trajectories of FBG data and their association with future MI risk were examined among the remaining 68,297 participants.

This investigation was in accordance with the guidelines of the Declaration of Helsinki and was approved by the ethics committees of the Kailuan Medical Group, Kailuan Group, and the Brigham and Women’s Hospital, Boston. All the participants gave their written informed consent.

Assessment of Incident MI

The outcome was the first occurrence of MI, either the first nonfatal MI event or MI death without past history of MI. To retrieve potential MI cases, the survey participants were linked to the Municipal Social Insurance Institution and all 11 Kailuan hospitals’ discharge registers, which covered all the Kailuan Group employees (i.e., all the Kailuan study participants). We used ICD-10 for the identification of potential MI (I21) (14). Additionally, information regarding past medical history of MI was collected by questionnaire biennially after 2006. A panel of three cardiologists reviewed the medical records of potential MI case subjects identified by the ICD code and/or questionnaire. MI was defined based on cardiac enzymes (i.e., levels of creatine kinase and troponin T or I), symptoms, electrocardiographic signs, and necropsy (15). Fatal MI, including sudden cardiac death due to cardiac arrest, was confirmed by hospital records or death certificates listing CHD or MI as the main cause of death.

Assessment of Covariates

Information on potential covariates was collected in 2006 and updated every 2 years thereafter, as detailed elsewhere (11,12,16,20). In brief, information on age, sex, smoking, alcohol intake, salt intake, physical activity, average monthly income, education level, and past self-reported medical history (e.g., hypertension, diabetes, and active treatment such as hypoglycemic agents, antihypertensive agents, lipid-lowering agents, and aspirin) was collected via questionnaire. Assessment of alcohol intake was
determined as follows: light drinker, 0.1–0.4 servings/day for women and 0.1–0.9 servings/day for men; moderate drinker, 0.5–1.5 servings/day for women and 1–2 serving/day for men; heavy drinker, >1.5 servings/day for women and >2 serving/day for men; based on 15 g of alcohol per day.

Height, weight, and blood pressure were measured by trained field workers (i.e., nurses) during the surveys. BMI was calculated as weight in kilograms divided by height in meters squared. Total cholesterol, triglycerides, HDL cholesterol (HDL-c), LDL cholesterol (LDL-c), creatinine, and hs-CRP were assessed by auto analyzer (Hitachi 747; Hitachi, Tokyo, Japan) at the central laboratory of Kailuan hospital. Estimated glomerular filtration rate (eGFR) was calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (21).

**Statistical Analysis**

All analyses were conducted using SAS version 9.3 (SAS Institute, Inc., Cary, NC). The person-time of follow-up for each participant was determined from the date when the message was collected in the 2010 survey to either the date of MI onset, death, loss to follow-up, or end of follow-up (31 December 2014), whichever came first. There were 2,439 (3.57%) participants who became lost to follow-up because of migrations or other reasons. We still included them in the analyses because they contributed person-time.

The FBG trajectories during 2006 to 2010 were identified by latent mixture modeling within the Proc Traj procedure (22,23). We used a censored normal model appropriate for continuous outcomes. Model fit was assessed using the Bayesian information criterion (BIC). We initiated a model with five trajectories and then compared the BIC to that with four, three, two, and one, respectively. The model with five patterns was identified as the best fit. We then compared the model with different functional forms. Cubic, quadratic, and linear terms were considered and evaluated based on their significance level, starting with the highest polynomial. In our final model, we had one pattern with a linear order term and four patterns with up to quadratic order terms. Cox proportional hazards model was used to investigate the association between exposures (e.g., the FBG trajectories and average FBG during 2006 to 2010) and risk of developing MI.

According to Schoenfeld residuals and log-log inspection, our models met the proportional assumption criteria. Results were adjusted for potential confounders, including age, sex, smoking, alcohol intake, education, physical activity, salt intake, income, updated use of antihypertensive and lipid-lowering agents and aspirin, average BMI, systolic blood pressure, diastolic blood pressure, eGFR, and average serum concentrations of triglycerides, HDL-c, LDL-c, and hs-CRP during 2006 to 2010. Missing data of these covariates were coded as an extra category. The moderate-stable pattern with the most participants (59.1%) was set as reference group to reach a stable model.

In a secondary analysis, we included only nonfatal MI as outcome by excluding 13 fatal MI cases. To examine whether the potential association between FBG trajectories and MI risk was due to a single measure of FBG during 2006 to 2010, we further adjusted for FBG concentrations in 2006 or 2010, one at a time. To explore whether the FBG–MI relation was explained by weight change, we conducted an analysis by adjusting for baseline BMI and annual weight change from 2006 to 2010 in the models. Likelihood ratio tests were conducted to examine statistical interactions between FBG trajectories and sex, age (<60 vs. ≥60 years), hypertension (yes vs. no), and BMI (<25 vs. ≥25 kg/m²) in relation to MI risk, by comparing −2 log likelihood χ² between nested models with and without the cross-product terms.

---

**Figure 1**—Trajectory of FBG during 2006–2010.
For more detailed analyses of the association between average FBG during 2006 to 2010 and subsequent MI risk, we also used restricted quadratic spline models (24) with 5 knots defined at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles of the FBG. To examine whether the potential association between high FBG and increased risk of MI was due to the higher likelihood of evolution to diabetes, we conducted a sensitivity analysis by excluding individuals who progressed to diabetes during 2010 to 2014. Because approximately one-third of the study participants worked underground in the coal mines, we conducted a sensitivity analysis after excluding these participants. Because some participants might develop other ischemic heart diseases during the follow-up, we also conducted a sensitivity analysis excluding the participants who self-reported use of aspirin and/or statins, which are routinely prescribed for all of these patients. Two-sided $P < 0.05$ was considered statistically significant in the current study.

**RESULTS**

We categorized the study population based on five observed discrete trajectories of FBG during 2006 to 2010 based on the FBG concentrations and changing patterns (Fig. 1): 5.7% ($n = 3,877$) of participants who consistently had elevated FBG concentrations (mean FBG concentrations ranged from 6.11 to 6.25 mmol/L during 2006 to 2010, referred to as “elevated-stable pattern”); 10.3% ($n = 7,060$) of participants who started with elevated concentrations and experienced a decrease (mean FBG concentrations decreased from 6.00 mmol/L in 2006 to 5.43 mmol/L in 2010, referred to as “elevated-decreasing pattern”); 15.1% ($n = 10,298$) of participants who started with moderate concentrations and experienced an increase (mean FBG concentrations increased from 5.20 mmol/L in 2006 to 5.80 mmol/L in 2010, referred to as “moderate-increasing pattern”); 59.1% ($n = 40,352$) of participants who maintained moderate FBG concentrations (mean FBG concentrations ranged from 4.85 to 5.08 mmol/L, referred to as “moderate-stable pattern”); and 9.8% ($n = 6,710$) of participants who maintained low FBG concentrations (mean FBG concentrations ranged from 4.20 to 4.47 mmol/L during 2006 to 2010, referred to as “low-stable pattern”). Individuals in the elevated-stable pattern were more likely to be men, have lower education, drink alcoholic beverages, use antihypertensive medications, and have concurrent cardiovascular risk factors (Table 1).

After a median follow-up of 3.9 years, we identified 283 incident MI cases. The elevated-stable FBG pattern experienced the highest future risk of developing MI among all five FBG patterns (Table 2). Relative to the moderate-stable pattern, adjusted HRs were 1.53 (95% CI 1.04, 2.26) for the elevated-stable pattern, 0.61 (95% CI 0.38, 0.98) for the elevated-decreasing pattern, 1.01 (95% CI 0.73, 1.38) for the moderate-increasing pattern, and 0.87 (95% CI 0.55, 1.37) for the low-stable pattern, after adjustment for potential confounders. Similar results were observed when we restricted to nonfatal MI cases. Further adjustment for the FBG in the 2006 or 2010 survey, for baseline BMI and weight change during 2006 to 2010, excluding participants who developed diabetes during 2010 to 2014, excluding coal-mine workers, or excluding participants who used aspirin or statins did not materially change the results (Table 2). We did not observe significant interactions between the FBG trajectories and sex, age, hypertension, and BMI in relation to MI risk (Supplementary Table 1) ($P$-interaction $>0.2$ for all).

**Table 1—Basic characteristics according to the FBG trajectory patterns during 2006 to 2010 among 68,297 Kailuan participants**

|                | Low-stable | Moderate-stable | Moderate-increasing | Elevated-decreasing | Elevated-stable |
|----------------|------------|-----------------|---------------------|---------------------|-----------------|
| $n$ (%)        | 6,170 (9.8)| 40,352 (59.1)   | 10,298 (15.1)       | 7,060 (10.3)        | 3,877 (5.7)     |
| Age, years     | 48.6       | 48.6            | 51.2                | 49.0                | 52.3            |
| Women, %       | 33.2       | 24.7            | 17.2                | 15.8                | 13.1            |
| Never smoker, %| 61.0       | 60.7            | 55.3                | 54.5                | 51.5            |
| Never alcohol intake, % | 60.1       | 58.4            | 51.5                | 51.2                | 47.6            |
| Physical activity ≥3 times/week, % | 14.1       | 13.2            | 15.1                | 14.7                | 15.9            |
| Salt intake ≥10 g/day, % | 8.9        | 9.7             | 11.6                | 10.9                | 13.3            |
| College/university, % | 10.3       | 8.5             | 5.2                 | 7.5                 | 5.0             |
| Average income ≥¥3,000/month, % | 7.3        | 6.7             | 5.9                 | 6.5                 | 6.1             |
| Use of antihypertensive agent, % | 11.7       | 13.0            | 18.3                | 16.5                | 20.8            |
| Use of lipid-lowering agents, % | 1.18       | 1.29            | 1.75                | 1.81                | 1.75            |
| Use of aspirin, % | 0.76       | 0.60            | 0.77                | 0.64                | 0.64            |
| BMI, kg/m²†    | 23.9       | 24.7            | 25.4                | 25.1                | 25.7            |
| hs-CRP, mg/mL† | 1.22       | 1.01            | 1.11                | 1.04                | 1.18            |
| TC, mmol/L†    | 4.75       | 4.89            | 5.10                | 5.01                | 5.24            |
| TG, mmol/L†    | 1.33       | 1.53            | 1.75                | 1.71                | 1.92            |
| HDL-c, mmol/L† | 1.56       | 1.53            | 1.55                | 1.53                | 1.54            |
| LDL-c, mmol/L† | 2.27       | 2.48            | 2.60                | 2.63                | 2.71            |
| SBP, mmHg†     | 124        | 127             | 131                 | 131                 | 135             |
| DBP, mmHg†     | 80         | 82              | 84                  | 84                  | 86              |
| eGFR, ml/min/1.73 m²† | 87.2     | 85.4            | 85.9                | 86.8                | 86.5            |

†Average concentrations based on measurements in 2006, 2008, and 2010. †Geometric mean. DBP, diastolic blood pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides.
In this prospective study of >68,000 adults without diabetes, we observed an elevated average FBG over 4 years, as well as heterogeneous FBG trajectories over a 4-year span. Individuals with stable and high FBG concentrations over 4 years were at higher subsequent MI risk. These findings add to the evidence that higher cumulative average glucose concentrations over 4 years were also associated with higher MI risk. Annual increment but not variability in FBG concentrations was significantly associated with risk of MI.

CONCLUSIONS

We observed that higher average FBG concentrations were associated with increased risk of MI and MIs. In a large prospective cohort of men and women, over a 4-year span, we observed that higher average FBG concentrations were associated with increased risk of MI and MIs. This finding is consistent with previous studies demonstrating the association between FBG and MI risk.

Table 2

| FBG Concentration (mmol/L) | Incidence Rate (per 1,000 person-years) | Adjusted HRs and 95% CIs for Risk of MI According to the FBG Trajectory Patterns during 2006 to 2010 Among 68,000 Korean Participants |
|---------------------------|----------------------------------------|--------------------------------------------------------------------------------|
| Low-stable | 1.13 (1.08, 1.18) | Adjustment for baseline BMI and annual weight change from 2006 to 2010* |
| Moderate-stable | 1.17 (1.12, 1.22) | Further adjustment for FBG in 2006* |
| Moderate-increasing | 1.22 (1.17, 1.28) | Further adjustment for FBG in 2010* |
| Elevated-decreasing | 1.25 (1.20, 1.30) | Multivariate model 1 |
| Elevated-stable | 1.30 (1.25, 1.35) | Multivariate model 2 |

Fig. 2

The present analyses showed a Jarque-Bera test for normality of the residuals. The results were consistent with previous studies demonstrating the association between elevated FBG concentrations and MI risk.
smoking, exercise, BMI, alcohol intake, and hypertension (26). However, another large study including 652,901 Koreans reported a nonsignificant relation regarding IFG and MI risk after adjustment for CHD risk factors, including hypertension, total cholesterol, and BMI (27). Of note, in these studies, MI events were documented from medical claims data and death report data without verification, which could introduce misclassification. In the Framingham Heart Study (FHS) (n = 4,138), IFG was significantly associated with a higher risk of cardiovascular disease in women but not in men during 4 years of follow-up (4). To our knowledge, no prior studies have examined the potential impacts of glucose trajectories on MI risk. Because of regression dilution, studies based on a single measure of glucose at baseline could underestimate the true association between IFG and MI risk (28). This notion is further supported by the observations that high cumulative average FBG, but not a single baseline assessment, significantly predicted future MI risk in the current analyses.

A previous study (n = 1,428) suggested that the risk for developing cardiovascular disease was confined to individuals with IFG who subsequently developed diabetes (8). In contrast, we observed that those with the elevated-stable pattern who had fasting glucose levels within the range of IFG had the greatest risk of MI even after we excluded those who developed diabetes during the follow-up, suggesting that the observed association might not be totally explained by the development of diabetes.

Substantial evidence supports the biological plausibility of our finding (29). First, insulin resistance in the prediabetes stage could promote atherogenesis and likely contributes to the elevated risk of cardiovascular disease (30). Second, IFG is associated with some preclinical pathological changes of MI, such as arterial stiffness, arterial endothelial dysfunction, and intima-media thickening (31,32). Furthermore, individuals with prediabetes usually have some coexisting MI risk factors (e.g., dyslipidemia, hypertension, obesity, physical inactivity, procoagulant state, and inflammation) (33,34). Consistently, we also observed that the elevated-stable pattern has higher prevalence of these risk factors relative to other patterns. Additional adjustment for these conventional cardiovascular risk factors, however, did not change the significant results.

We found that for participants with average FBG concentrations of 5.7 mmol/L or higher, risk of MI increased with an increase in FBG concentrations. We also observed that decrease in FBG over time was associated with a subsequently reduced risk of MI. These findings suggest that regularly monitoring FBG among individuals with a glucose level in the range of IFG (5.6–6.9 mmol/L) is of significance for public health and clinical practice because these individuals are generally not

**Table 3—Adjusted HRs and 95% CIs for risk of MI, according to FBG concentrations in 2010 and cumulative average, annual increase rate, and variability of FBG from 2006 to 2010**

| FBG concentrations | P-trend* |
|--------------------|---------|
| FBG in 2010        |         |
| Range, mmol/L      |         |
| Cases, n (person-years) |         |
| Incidence rate, per 1,000 person-years |         |
| HR (95% CI)†       |         |
| Range, mmol/L      |         |
| Cases, n (person-years) |         |
| Incidence rate, per 1,000 person-years |         |
| HR (95% CI)†       |         |
| Range, mmol/L per year |         |
| Cases, n (person-years) |         |
| Incidence rate, per 1,000 person-years |         |
| HR (95% CI)†       |         |
| Range, mmol/L      |         |
| Cases, n (person-years) |         |
| Incidence rate, per 1,000 person-years |         |
| HR (95% CI)†       |         |
| Range, mmol/L      |         |
| Cases, n (person-years) |         |
| Incidence rate, per 1,000 person-years |         |
| HR (95% CI)†       |         |

*For tests of trend, the median value in each category was used as a continuous variable. †Model adjusted for age (years), sex, smoking (current, past, or never), alcohol intake (never, past, light, moderate, or heavy), education (illiteracy or elementary school, middle school, or college/university), physical activity (never, sometimes, or active), average monthly income of each family member (<500, 500–3,000, or >3,000), salt intake (>10, 6–10, or <6 g/day), updated use of antihypertensive and lipid-lowering agents and aspirin (yes/no for each), average BMI (≥30, 25–29.9, or <25 kg/m²), systolic blood pressure (quintile), diastolic blood pressure (quintile), eGFR (quintile), average serum concentrations of triglycerides (quintile), HDL-c (quintile), and hs-CRP (<1, 1–3, or ≥3 mg/mL) during 2006 to 2010.**
treated, although they may experience high future MI risk. This is particularly important given that lifestyle intervention could effectively lower glucose concentrations (35,36).

Our study has several limitations. Oral glucose tolerance testing, casual random concentrations (35,36). could effectively lower glucose concentrations and self-report physician diagnosis, and the impact of underdiagnoses of diabetes on the observed association between FBG trajectory and MI risk could be small. Further, the primary aim of our study was to examine whether FBG in those without diabetes rather than diabetes diagnosis itself was associated with MI risk. Current guidelines do not recommend the routine use of oral glucose tolerance testing for diabetes screening among the general population (37). We did not collect information regarding coronary intervention for other kinds of ischemic heart disease in the current study, which could confound the observed association between FBG trajectories and MI risk. However, in the sensitivity analysis, by excluding the aspirin/statin users, we observed similar results. The current study included only Chinese adults living in the Kailuan community, and the trajectories identified in this population thus may not be generalizable to other populations. However, the biological effects of high FBG on cardiovascular health in this cohort should be the same as those among men and women in general. The homogeneous nature of our cohort could help to reduce potential confounding due to racial and health care disparities and, therefore, enhance internal validity, which is a prerequisite for the generalizability.

**Conclusion**

We identified five discrete FBG trajectories and found that these patterns were significantly associated with subsequent risk of developing MI in individuals without diabetes. Monitoring trajectories of FBG may provide an important approach to identify a population with higher risk of MI and help to prevent primary MI in a population without diabetes. Future research needs to explore the key risk factors that are associated with the elevated BP trajectories. Studies in populations with different racial and ethnic compositions and those that include data on HbA1c are also warranted to replicate our findings.

**Acknowledgments.** The authors thank all the members of the Kailuan Study Team for their contribution and the participants who contributed their data.

**Funding.** The study was supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (RO1 DK107407), the Doris Duke Charitable Foundation (grant 2015085), the National Institutes of Health National Heart, Lung, and Blood Institute (K23HL111771), and the National Institute of Neurological Disorders and Stroke (R21NS087235-02).

The funding agencies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** C.J., S.W., and X.G. contributed to the study concept and design. C.J. and X.G. drafted the manuscript. C.J. performed statistical analysis. S.W. and X.G. supervised the study. All authors contributed to the acquisition, analysis, or interpretation of data and to the critical revision of the manuscript for important intellectual content. S.W. and X.G. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**References**

1. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222
2. Tancredi M, Rosengren A, Svensson A-M, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med 2015;373:1720–1732
3. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829–841
4. Levitzky YS, Pencina MJ, D’Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008;51:264–270
5. Barr EL, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151–157
6. Danafar G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006;368:1651–1659
7. Levitan EB, Song Y, Ford ES, Liu S. Is non-diabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147–2155
8. Rijkenhuijsen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Dekker JM. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: the Hoorn study. Diabetes Care 2007;30:332–336
9. Liu J, Grundy SM, Wang W, et al. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. Am Heart J 2007;153:552–558
10. Wu S, Huang Z, Yang X, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a northern Chinese industrial city. Circ Cardiovasc Qual Outcomes 2012;5:487–493
11. Huang S, Li J, Shearer GC, et al. Longitudinal study of alcohol consumption and HDL concentrations: a community-based study. Am J Clin Nutr 2012;95:905–912
12. Wu Z, Huang Z, Jin W, et al. Peripheral inflammatory biomarkers for myocardial infarction risk: a prospective community-based study. Clin Chem 2017;63:663–672
13. Wong JC, Li J, Pavlova M, et al. Risk factors for probable REM sleep behavior disorder: a community-based study. Neurology 2016;86:1306–1312
14. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007;28:2525–2538
15. Thygesen K, Alpert JS, Jaffe AS, et al.; Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–1598
16. Wang L, Cui L, Wang Y, et al. Resting heart rate and the risk of developing impaired fasting glucose and diabetes: the Kailuan prospective study. Int J Epidemiol 2015;44:689–699
17. Sequist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384–1395
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(Suppl. 1):S81–S90
19. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermedi ate Hyperglycaemia: Report of a WHO/IDF Consultation. Geneva, World Health Organization, 2006
20. Wu Z, Jin C, Vaidya A, et al. Longitudinal patterns of blood pressure, incident cardiovascular events, and all-cause mortality in normotensive diabetic people. Hypertension 2016;68:71–77
21. Stevens LA, Claborn MA, Schmid CH, et al. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int 2011;79:555–562
22. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res 2001;29:374–393
23. Jones BL, Nagin DS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Social Methods Res 2007;35:542–571.

24. Li R, Hertzmark E, Louie M, Chen L, Spiegelman D. The SAS LGTPHCURV9 Macro. Boston, MA, Channing Laboratory, 2011.

25. Genuith S, Alberti KG, Bennett P, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3167.

26. Park C, Guallar E, Linton JA, et al. Fasting glucose level and the risk of incident atherosclerotic cardiovascular diseases. Diabetes Care 2013;36:1988–1993.

27. Sung J, Song Y-M, Ebrahim S, Lawlor DA. Fasting blood glucose and the risk of stroke and myocardial infarction. Circulation 2009;119:812–819.

28. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341–353.

29. Chait A, Bornfeldt KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipid Res 2009;50(Suppl.):S335–S339.

30. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010;33:442–449.

31. van Popele NM, Elizabeth Hak A, Mattace-Raso FU, et al. Impaired fasting glucose is associated with increased arterial stiffness in elderly people without diabetes mellitus: the Rotterdam Study. J Am Geriatr Soc 2006;54:397–404.

32. Thomas GN, Chook P, Qiao M, et al. Deleterious impact of “high normal” glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004;24:739–743.

33. DeFronzo RA, Abdul-Ghani M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 2011;108(Suppl.):38–248.

34. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol 2012;59:635–643.

35. Sui X, Jackson AS, Church TS, et al. Effects of cardiorespiratory fitness on aging: glucose trajectory in a cohort of healthy men. Ann Epidemiol 2012;22:617–622.

36. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014;2:474–480.

37. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S5–S20.